Benzinga · Nov 6, 2026
Freedom Broker Downgrades Amgen to Hold, Raises Price Target to $470
Freedom Broker analyst Ilya Zubkov downgrades Amgen (NASDAQ:AMGN) from Buy to Hold and raises the price target from $450 to $470.
AM
NYSE · AMGN
Amgen Inc.
Healthcare · Drug Manufacturers - General
$460.42
Up+$0.14 (+0.03%)
Updated Nov 8, 2026, 8:39 AM
SID Score
7.5/10
Composite research score
Smart Money
45/100
Neutral
- Market cap
- 209.24B
- P/E ratio
- 27.13
- Dividend yield
- 2.62%
- 52-week range
- $319.79 – $483.99
- Volume
- 2.58M
- Avg. volume
- 2.89M
Price performance · AMGN
AMGN price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 6, 2026
AMGN closed at $460.42 after 20 trading sessions, up 10.26% for the selected period.
- Last close
- $460.42
- Period change
- +10.26%
- Period low
- $412.84
- Period high
- $478.48
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 6, 2026 | $448.165 | $462.91 | $447.04 | $460.42 | 2.58M |
| Nov 5, 2026 | $483.99 | $483.99 | $459.6488 | $460.28 | 4.11M |
| Nov 4, 2026 | $479.61 | $482.48 | $464.13 | $478.48 | 4.62M |
| Nov 3, 2026 | $463.38 | $467.04 | $460.15 | $461.26 | 2.38M |
| Nov 2, 2026 | $463.43 | $469.00 | $461.00 | $465.45 | 3.2M |
| Oct 30, 2026 | $470.15 | $475.645 | $465.33 | $466.01 | 3.29M |
| Oct 29, 2026 | $465.57 | $468.27 | $457.355 | $460.73 | 2.98M |
| Oct 28, 2026 | $441.03 | $454.66 | $439.57 | $451.83 | 2.91M |
| Oct 27, 2026 | $441.80 | $448.545 | $439.2801 | $447.95 | 1.73M |
| Oct 26, 2026 | $444.89 | $449.80 | $439.50 | $444.63 | 2.05M |
| Oct 23, 2026 | $444.40 | $444.59 | $439.07 | $439.26 | 2.07M |
| Oct 22, 2026 | $441.55 | $450.98 | $437.1944 | $447.28 | 3.11M |
| Oct 21, 2026 | $440.21 | $441.03 | $434.53 | $438.34 | 2.61M |
| Oct 20, 2026 | $425.58 | $439.05 | $425.11 | $438.94 | 2.22M |
| Oct 19, 2026 | $430.355 | $434.51 | $424.74 | $424.94 | 2.68M |
| Oct 16, 2026 | $437.89 | $438.82 | $431.39 | $432.49 | 2.57M |
| Oct 15, 2026 | $435.83 | $441.7599 | $433.42 | $434.03 | 4.63M |
| Oct 14, 2026 | $417.83 | $428.05 | $415.1951 | $426.11 | 3.09M |
| Oct 13, 2026 | $420.34 | $420.35 | $411.04 | $412.84 | 2.32M |
| Oct 12, 2026 | $416.12 | $417.76 | $413.44 | $417.57 | 1.72M |
Latest AMGN news
The latest Smart Investors Daily articles mentioning AMGN.
Stock researchCompany · Overview
Company
Market Activity
Research & News
AMGN research
Overview
Company profile and research snapshot.
Company profile
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $368.50
- Implied upside
- —
- Analysts
- 23
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 6, 2026 | Freedom Broker | Hold | — |
| Nov 5, 2026 | Leerink Partners | Market Perform | — |
| Nov 5, 2026 | Guggenheim | Neutral | — |
| Nov 4, 2026 | Cantor Fitzgerald | Neutral | — |
| Nov 4, 2026 | Scotiabank | Sector Outperform | — |
News briefing
Generated Nov 7, 2026, 9:03 PM
What's Happening With AMGN? Strong Fundamentals Meet Mixed Analyst Signals
Amgen is treading water today with a marginal gain of just $0.14 (0.03%), as the market digests a mixed bag of analyst activity and positive clinical data. While multiple brokerages are adjusting price targets upward and the company reported encouraging real-world evidence for its cardiovascular drug Repatha, analyst sentiment remains cautiously neutral rather than enthusiastically bullish.
Bottom line: Amgen is firing on multiple cylinders with positive clinical data, steady institutional demand, and strategic progress on RNA therapeutics and rare disease initiatives—yet analyst sentiment remains surprisingly muted, likely reflecting valuation concerns after the stock's impressive 46% year-to-date run. Investors should monitor whether Repatha's real-world efficacy data translates into meaningful market share gains and whether the company's rare disease and RNA pipelines can justify current valuations. The key risk remains that continued elevated valuation multiples may limit upside without accelerating revenue growth from new product launches.
Yahoo · Nov 6, 2026
57 ETFs Add to Amgen (AMGN) Holdings on Wednesday
ETFs bought a net $79.8 million of Amgen stock in Wednesday's session.
Yahoo · Nov 6, 2026
While biotech bets swing on trial data, this dividend payer gained 72% since 2024
Investing.com and Yahoo Finance LLC may earn commission or revenue on some items through the links below.
Yahoo · Nov 5, 2026
BeOne Medicines Ltd (ONC) Q3 2026 Earnings Call Highlights: Brukinsa Tops $1 Billion in U.S. ...
BeOne Medicines Ltd (ONC) raised full-year 2026 revenue guidance to $6.9-$7.0 billion on strong Brukinsa momentum, despite a delayed BTK degrader filing and looming biosimilar headwinds.
AI research layers
Interpretive context generated from the platform’s current data sources.
Amgen Inc. Stock Performance
Amgen Inc. shares closed at $460.42, reflecting a single-session decline of approximately 2.50% per SID market data. Despite the daily pullback, the stock has demonstrated consistent upward momentum across multiple timeframes, gaining 11.43% over the past month and 12.01% over the trailing three months. On a twelve-month basis, AMGN has appreciated 39.43%, significantly outpacing many healthcare peers. The stock currently trades well above both its 50-day moving average of $421.96 and its 200-day moving average of $379.19, confirming a sustained bullish technical trend. The 14-day relative strength index stands at 63.1, indicating positive momentum without entering overbought territory. Average daily trading volume registers at approximately 2.89 million shares, according to Massive/Polygon data. Amgen's beta of 0.472 reflects meaningfully lower volatility than the broader market, consistent with its defensive healthcare sector positioning and established large-cap profile.
Amgen Inc. Valuation Analysis
Amgen Inc. carries a market capitalization of approximately $209.2 billion, positioning it among the largest biotechnology companies globally. Per SID market data, the stock trades at a price-to-earnings ratio of 27.13, which sits above the historical average for large-cap biopharmaceuticals and reflects investor expectations for continued earnings growth. The PEG ratio of 2.72 suggests that the current P/E multiple is elevated relative to the company's projected earnings growth rate, indicating the stock may be pricing in substantial pipeline or revenue expansion. Amgen's price-to-book ratio stands at 24.16, a figure influenced by the company's capital structure and significant intangible asset base accumulated through acquisitions, per SEC filings. The company maintains a dividend yield of approximately 2.49%, providing a meaningful income component for shareholders. Within the healthcare sector, this yield remains competitive relative to peers of similar market capitalization and growth profile.
Smart Money Activity for AMGN
Amgen Inc. registers a composite smart money score of 45 out of 100 with a neutral overall signal, according to SID market data. The institutional ownership sub-score stands at a perfect 25 out of 25, reflecting robust conviction from large asset managers and funds, per 13F institutional filings. Insider activity shows a sub-score of 2.4 out of 25, though recent SEC Form 4 filings reveal seven insider transactions over the past 90 days, comprising five purchases and two sales. The favorable buy-to-sell ratio among insiders suggests a degree of internal confidence in the company's near-term trajectory. Dark pool activity registers at 8.5 out of 25, indicating moderate institutional block trading volumes. Congressional trading activity scores 8.8 out of 25, reflecting limited but notable legislative interest. The divergence between the strong institutional score and lower insider and dark pool readings contributes to the overall neutral composite assessment, suggesting mixed sentiment among different categories of sophisticated market participants.
Amgen Inc. Earnings Outlook
Amgen Inc. has delivered four consecutive quarters of earnings beats, according to company earnings reports. In the most recent quarter reported in early November 2026, the company posted earnings per share of $6.45, surpassing the consensus analyst estimate of $5.77 by $0.68, representing an 11.8% positive surprise. The prior quarter similarly exceeded expectations, with actual EPS of $6.29 versus the $5.60 estimate, a $0.69 beat. The April 2026 quarter produced EPS of $5.15 against a $4.76 estimate, while the February report showed $5.29 versus the $4.75 consensus. Across these four periods, the average earnings surprise was approximately $0.58 per share, demonstrating a consistent pattern of management guidance conservatism or operational outperformance. The sequential EPS progression from $5.29 to $6.45 represents meaningful growth over the trailing four quarters, per analyst estimates, indicating accelerating profitability driven by the company's commercial portfolio.
Wall Street Analyst Ratings for AMGN
Wall Street analyst sentiment on Amgen Inc. reflects a mixed but stable consensus, per SID consensus data. In the most recent round of coverage updates following the November 2026 earnings report, five analyst firms reiterated their existing ratings without changes. UBS maintained its Buy rating, representing the most bullish stance among recent updates, while Scotiabank reaffirmed its Sector Outperform classification. On the neutral side, Leerink Partners reiterated a Market Perform rating, Guggenheim maintained Neutral, and Cantor Fitzgerald also held at Neutral, according to Wall Street analyst reports. Notably, none of the five covering analysts issued downgrades or upgrades, suggesting the earnings beat was largely in line with buy-side expectations despite exceeding published consensus estimates. The distribution of three neutral ratings against two positive ratings indicates a cautious tilt among the analyst community, potentially reflecting concerns around the stock's current valuation metrics, including the 27.13 P/E ratio and 2.72 PEG ratio relative to growth prospects.
